Identifying the Cellular Target of Cordyheptapeptide A and Synthetic Derivatives
- PMID: 34251165
- PMCID: PMC8545353
- DOI: 10.1021/acschembio.1c00094
Identifying the Cellular Target of Cordyheptapeptide A and Synthetic Derivatives
Abstract
Cordyheptapeptide A is a lipophilic cyclic peptide from the prized Cordyceps fungal genus that shows potent cytotoxicity in multiple cancer cell lines. To better understand the bioactivity and physicochemical properties of cordyheptapeptide A with the ultimate goal of identifying its cellular target, we developed a solid-phase synthesis of this multiply N-methylated cyclic heptapeptide which enabled rapid access to both side chain- and backbone-modified derivatives. Removal of one of the backbone amide N-methyl (N-Me) groups maintained bioactivity, while membrane permeability was also preserved due to the formation of a new intramolecular hydrogen bond in a low dielectric solvent. Based on its cytotoxicity profile in the NCI-60 cell line panel, as well as its phenotype in a microscopy-based cytological assay, we hypothesized that cordyheptapeptide was acting on cells as a protein synthesis inhibitor. Further studies revealed the molecular target of cordyheptapeptide A to be the eukaryotic translation elongation factor 1A (eEF1A), a target shared by other lipophilic cyclic peptide natural products. This work offers a strategy to study and improve cyclic peptide natural products while highlighting the ability of these lipophilic compounds to effectively inhibit intracellular disease targets.
Figures
Similar articles
-
Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex.Elife. 2015 Dec 10;4:e10222. doi: 10.7554/eLife.10222. Elife. 2015. PMID: 26651998 Free PMC article.
-
Inhibition of protein synthesis by didemnin B: how EF-1alpha mediates inhibition of translocation.Biochemistry. 2000 Apr 18;39(15):4339-46. doi: 10.1021/bi992202h. Biochemistry. 2000. PMID: 10757982
-
Total Synthesis and Pharmacological Investigation of Cordyheptapeptide A.Molecules. 2017 May 27;22(6):682. doi: 10.3390/molecules22060682. Molecules. 2017. PMID: 28554994 Free PMC article.
-
Monocyclic Peptides: Types, Synthesis and Applications.Curr Pharm Biotechnol. 2021;22(1):123-135. doi: 10.2174/1573412916666200120155104. Curr Pharm Biotechnol. 2021. PMID: 31987019 Review.
-
The eEF1A protein in cancer: Clinical significance, oncogenic mechanisms, and targeted therapeutic strategies.Pharmacol Res. 2024 Jun;204:107195. doi: 10.1016/j.phrs.2024.107195. Epub 2024 Apr 25. Pharmacol Res. 2024. PMID: 38677532 Review.
Cited by
-
Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art.Int J Mol Sci. 2023 Mar 8;24(6):5184. doi: 10.3390/ijms24065184. Int J Mol Sci. 2023. PMID: 36982256 Free PMC article. Review.
-
Didemnin B and ternatin-4 differentially inhibit conformational changes in eEF1A required for aminoacyl-tRNA accommodation into mammalian ribosomes.Elife. 2022 Oct 20;11:e81608. doi: 10.7554/eLife.81608. Elife. 2022. PMID: 36264623 Free PMC article.
-
Site-directed late-stage diversification of macrocyclic nannocystins facilitating anticancer SAR and mode of action studies.RSC Med Chem. 2022 Dec 22;14(2):299-312. doi: 10.1039/d2md00393g. eCollection 2023 Feb 22. RSC Med Chem. 2022. PMID: 36846368 Free PMC article.
-
Interaction of Acinetobacter sp. RIT 592 induces the production of broad-spectrum antibiotics in Exiguobacterium sp. RIT 594.Front Pharmacol. 2024 Aug 1;15:1456027. doi: 10.3389/fphar.2024.1456027. eCollection 2024. Front Pharmacol. 2024. PMID: 39148551 Free PMC article.
References
-
- Bockus AT; McEwen CM; Lokey RS, Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective. Curr. Top. Med. Chem 2013, 13 (7), 821–836. - PubMed
-
- Zorzi A; Deyle K; Heinis C, Cyclic Peptide Therapeutics: Past, Present and Future. Curr. Opin. Chem. Biol 2017, 38, 24–29. - PubMed
-
- Marsault E; Peterson ML, Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery. J. Med. Chem 2011, 54 (7), 1961–2004. - PubMed
-
- Driggers EM; Hale SP; Lee J; Terrett NK, The Exploration of Macrocycles for Drug Discovery - an Underexploited Structural Class. Nat. Rev. Drug Discovery 2008, 7, 608–624. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
